Global healthcare experienced a complete paradigm shift when multiplex biomarker imaging was introduced to map tumor cells. A market for global multiplex biomarker imaging techniques grew out of the need to upgrade from standard imaging methods such as flow cytometry to more advanced methods. This technique allows more complex and complete details of tumor anatomy to be received. Doctors and analysts have benefited tremendously from the multiplex biomarker imaging technique, thereby helping the market grow across the world.
The global multiplex biomarker imaging market is driven by the rising demand for efficacious drugs for various types of cancer. Many biosciences companies use advanced multiplex biomarker imaging techniques for oncology research. Funding made by these companies and their governments for cancer research, especially lung and blood cancer, has created profitable avenues for the global multiplex biomarker imaging market.
The advantages of the multiplex biomarker imaging technique are cost effectiveness and the ability to make an analysis of thousands of tissues in a single turn. The multiplex biomarker imaging also provides hemoglobin status, exact location of tumor, and apoptosis presence, among others. The global multiplex biomarker imaging market is gaining growth momentum from regions such as the Asia-Pacific, North America and Europe. These regions have made massive progressive strides in cancer biology and high quality cancer assessment systems.
The complex process involved in detection and analysis, stringent policies of the government, and ethical issues surrounding the technique have put certain restraints on the growth of the global multiplex biomarker imaging market and might bear negative consequences in the long term. Nonetheless, many bioscience companies are investing substantially for developing better reagents to support the market.
Research On Global Markets 